Company news

Idorsia Ltd. news in 2025

Idorsia Ltd.'s news releases, calls and decks from 2025, newest first.

View company

New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD

December 10, 2025

Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category

December 9, 2025

Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension

November 10, 2025

Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions

November 5, 2025

QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results

October 30, 2025

Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability

October 10, 2025

Idorsia launches an offering of registered shares – to fund the company to overall profitability

October 9, 2025

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China

September 22, 2025

Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

September 19, 2025

Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025

September 10, 2025

Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025

September 8, 2025

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension

September 5, 2025

Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call

September 3, 2025

Idorsia furthers the science of sleep and insomnia at World Sleep 2025

September 1, 2025

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

August 28, 2025

Idorsia successfully completes convertible bonds restructuring

August 27, 2025

TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension

August 19, 2025

Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds

August 19, 2025

TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”

August 12, 2025

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

August 11, 2025

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results

July 30, 2025

Invitation to Idorsia's HY 2025 Financial Reporting webcast and conference call with our new CEO Srishti Gupta

July 23, 2025

A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans

June 30, 2025

Bondholders approve amended terms of the 2025 and 2028 convertible bonds

June 25, 2025

Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds

June 25, 2025

Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement

June 23, 2025

Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia

June 10, 2025

Idorsia publishes invitations to bondholder meetings

June 6, 2025

Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025

May 28, 2025

New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability

May 21, 2025

Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

May 2, 2025

Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset

April 30, 2025

New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine

April 29, 2025

Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond

April 16, 2025

The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension

April 9, 2025

US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement

April 9, 2025

Idorsia publishes its Annual Report 2024

March 27, 2025

US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients

March 17, 2025

Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

March 14, 2025

Idorsia announces financial results for 2024

March 4, 2025

Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call

February 27, 2025

Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations

February 26, 2025

Idorsia and Viatris update their collaboration for selatogrel and cenerimod

February 26, 2025

Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties

February 26, 2025

Bondholders approve amended terms of the 2025 convertible bonds

February 25, 2025

Calls in 2025

Decks in 2025